Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Core Insights - Enable Injections, Inc. has received a $30 million investment from Sanofi to enhance its manufacturing capabilities and support commercial growth of the enFuse® On-Body Delivery System [1][2] Company Overview - Enable Injections is a healthcare innovation company based in Cincinnati, focused on developing the enFuse® On-Body Delivery System, which aims to improve patient treatment experiences by delivering large volumes of medications subcutaneously [6][7] - The enFuse system is designed to provide convenient administration of large-volume injectable therapies, particularly in oncology [2][6] Investment and Financials - The recent $30 million investment follows a history of financial support from Sanofi, which previously led a $50 million Series B round in 2018 and participated in a $215 million Series C financing in January 2022 [4] - Enable has also received backing from other institutional investors and organizations, including Cincinnati Children's Hospital Medical Center and Ohio Innovation Fund [4] Manufacturing and Expansion Plans - Enable announced plans for a 90,000 square foot Manufacturing Center of Excellence in Springdale, Ohio, to bolster in-house manufacturing capabilities [5] - The company is committed to enhancing its corporate headquarters in Evendale, Ohio, as part of its commercialization efforts [5] Clinical Trials and Regulatory Status - The enFuse system has been utilized in clinical studies for Sanofi's Sarclisa, with ongoing regulatory reviews for its use in specific formulations [3][7] - The technology received its first combination product U.S. FDA approval in 2023 and has obtained marketing authorizations from several international regulatory bodies [7]